Verdict archive
Browse every verdict Pep has written — each peptide read down to the studies and handed an honest call: 🟢 proven, 🔵 promising, 🟡 unproven, or 🔴 risky.
Showing all 40 verdicts
GLP-1PromisingAmycretin is an early-stage, investigational molecule with intriguing dual-pathway design and early trial figures that drew real attention - but the human evidence is still small, short, and unconfirmed. Promising on the early data; unproven until larger trials read out. It is not FDA-approved and not available for human use.
Jul 8, 2026 · MrPepTalks Editorial · 4 min read
GLP-1PromisingA genuinely novel appetite peptide with a clever AI-driven origin and clean early animal data — reported to work through a non-GLP-1 pathway with no nausea in mice and pigs. But the entire file is preclinical: no human has ever been dosed, it is not approved, and it is not available for human use. Promising, and honestly unproven.
Jul 8, 2026 · MrPepTalks Editorial · 5 min read
CognitiveUnprovenDSIP has a memorable discovery story and decades of scattered study, but the human sleep evidence is old, small, and famously hard to replicate, and several studies reported no reliable effect. That combination earns an unproven label: it is genuinely researched, not a scam, but it has not been confirmed as a dependable sleep aid, and the size of the unknown is still large.
Jul 8, 2026 · MrPepTalks Editorial · 6 min read
PerformanceUnprovenFollistatin 344 is a real myostatin-binding protein commonly researched for muscle growth, and the animal data is genuinely striking. But human evidence is extremely limited, resting on one early gene-therapy trial rather than trials of the research peptide, with no validated human protocol. It is not FDA-approved and falls under anti-doping prohibitions.
Jul 8, 2026 · MrPepTalks Editorial · 4 min read
PerformanceUnprovenGHRP-2 reliably prompts short-term growth hormone release in early human studies, which is why it was explored as a GH-testing agent. But controlled human data on physique, recovery, or aging-related outcomes is missing, and it comes with higher cortisol, prolactin, and appetite. Not FDA-approved, sold for research use only, and banned in sport.
Jul 8, 2026 · MrPepTalks Editorial · 5 min read
PerformanceUnprovenGHRP-6 prompts short-term growth hormone release in early human studies and reliably increases appetite through the ghrelin receptor. But controlled human data on physique, recovery, or aging-related outcomes is missing, and it comes with intense hunger, water retention, and modest cortisol and prolactin rises. Not FDA-approved, sold for research use only, and banned in sport.
Jul 8, 2026 · MrPepTalks Editorial · 5 min read
PerformanceUnprovenCommonly researched as a strong GH-releasing peptide, with a distinctive CD36-linked cardiac signal in animals. The human outcome file is thin, so the honest verdict stays Unproven. It is not FDA-approved and is prohibited in sport.
Jul 8, 2026 · MrPepTalks Editorial · 5 min read
RecoveryUnprovenLL-37 has a large and genuinely interesting laboratory record across antimicrobial activity, immune signaling, and wound healing, which is why it keeps coming up. But the evidence for a supplemented human benefit is minimal, and the same peptide is also implicated in inflammatory conditions, so this is one of the clearest cases where the honest verdict is interesting-but-unsettled rather than a green light.
Jul 8, 2026 · MrPepTalks Editorial · 7 min read
GLP-1PromisingMazdutide is one of the few research peptides with genuine human trial data and a real regulatory approval behind it — it is commonly researched for weight and metabolic outcomes, and its glucagon/GLP-1 dual design is the reason it stands out. It is not FDA-approved in the United States, remains investigational there, and the research-grade material sold for lab use is not the reviewed product, so an honest read holds the strong data and the real caveats together.
Jul 8, 2026 · MrPepTalks Editorial · 6 min read
SkincareRiskyMelanotan 2 has a real melanocortin mechanism and some early human research behind its pigmentation and arousal effects, but the safety file is what defines it: documented changing moles, cases linked to melanoma, priapism, and a completely unregulated gray-market supply. It is not FDA-approved, and regulators have warned against it. Risky is the honest read.
Jul 8, 2026 · MrPepTalks Editorial · 6 min read
GLP-1PromisingAn investigational GLP-1/glucagon dual agonist with early human trial figures that look interesting for weight and liver-fat outcomes. The catch: the human file is still Phase 2, longer-term safety is not settled, and it is not approved or available. Promising on early evidence, unproven until larger trials land.
Jul 8, 2026 · MrPepTalks Editorial · 4 min read
PerformanceUnprovenSermorelin is a genuinely clever GHRH analog with a real clinical past as a diagnostic and pediatric agent. The popular adult age-reversal and body-composition uses, though, rest on GH and IGF-1 marker changes rather than large trials measuring how people actually look, feel, or perform. It is not currently FDA-approved and it sits on the WADA prohibited list.
Jul 8, 2026 · MrPepTalks Editorial · 5 min read
SkincarePromisingA topical peptide with a plausible mechanism and early cosmetic data for softening expression lines, held back by one honest question: how much of a large peptide actually crosses intact skin. Encouraging for the topical form, not a stand-in for an injection, and not FDA-approved.
Jul 8, 2026 · MrPepTalks Editorial · 6 min read
GLP-1PromisingMid-stage trials reported meaningful weight and liver-marker changes, and the dual-target design is genuinely interesting. But survodutide is still investigational: it is not FDA-approved, not available for human use, and larger confirmatory trials are the ones that will decide whether Promising becomes Proven.
Jul 8, 2026 · MrPepTalks Editorial · 5 min read
GLP-1PromisingVK2735 is one of the more interesting pipeline peptides because its early human data comes in two forms — an injectable and an oral tablet — and it is commonly researched for weight management. It is still investigational and not FDA-approved, it has no phase-3 outcome data yet, and the research-grade material sold for lab use is not the trial drug, so an honest read holds the encouraging early signal and the real caveats together.
Jul 8, 2026 · MrPepTalks Editorial · 6 min read
RecoveryUnprovenKPV shows a consistent anti-inflammatory signal across cell and animal models of gut and skin inflammation, which is genuinely interesting for a fragment this small. But the evidence is almost entirely preclinical: the controlled human trials that would turn an interesting signal into an established benefit essentially do not exist yet, so this stays unproven rather than a green light.
Jul 7, 2026 · MrPepTalks Editorial · 6 min read
CognitivePromisingSelank has something most research peptides in this corner lack: an actual human anxiety signal, reported in small clinical studies. But that evidence is thin, mostly from one country, and largely unreplicated in big Western trials, so it earns a promising label rather than a proven one, with the honest caveat that the size of the unknown is still large.
Jul 7, 2026 · MrPepTalks Editorial · 6 min read
CognitiveUnprovenSemax has a genuinely interesting research history and a plausible mechanism through BDNF, but the evidence is early-stage and lopsided, concentrated in Russian-language studies with few independent English-language trials to confirm it. The cognitive and neuroprotective benefits people want are not established, which keeps this an open question rather than a green light.
Jul 7, 2026 · MrPepTalks Editorial · 6 min read5-Amino-1MQ has a genuinely interesting mechanism and some encouraging early animal work behind it — but the human evidence simply is not there yet. It is an early-stage research compound, not a finished answer, and it is not FDA-approved. The mechanism deserves attention; the hype deserves a caveat.
Jul 6, 2026 · MrPepTalks Editorial · 8 min read
PerformanceUnprovenAOD-9604 has a neat mechanism and reached human clinical development, which is more than a lot of research compounds can claim. But that obesity program was discontinued without approval, so the headline fat-loss benefit people chase stays unestablished rather than confirmed, and that gap is the whole story.
Jul 6, 2026 · MrPepTalks Editorial · 6 min readLoads of promising animal research, a devoted following that reports fast recovery, and almost no controlled human trials to back any of it. Commonly researched for tissue repair and gut health — but until real human data lands, BPC-157 stays unproven, and it is not FDA-approved.
Jul 6, 2026 · MrPepTalks Editorial · 4 min read
GLP-1PromisingCagrilintide is one of the rarer research peptides with genuine human trial data, most of it generated as the amylin half of the investigational CagriSema combination with semaglutide. That data is real and is centered on body-weight endpoints — but cagrilintide on its own is investigational, not FDA-approved, and its long-term and standalone picture is still open.
Jul 6, 2026 · MrPepTalks Editorial · 6 min read
PerformanceUnprovenCJC-1295 does something measurable in research — it raises growth-hormone and IGF-1 markers — but the human evidence stops there. Controlled trials on the body-composition and performance outcomes people actually chase are essentially absent, so the honest label is unproven, not proven and not dismissed.
Jul 6, 2026 · MrPepTalks Editorial · 6 min read
LongevityUnprovenEpitalon has a real and genuinely interesting laboratory story around telomerase and aging markers, plus small early human studies. But almost all of it traces back to a narrow set of research groups, independent replication is thin, and no long-term blinded human trial establishes a longevity benefit. Fascinating, and unproven.
Jul 6, 2026 · MrPepTalks Editorial · 6 min readTopical GHK-Cu earns a Promising verdict on the strength of small human cosmetic studies for skin firmness and fine lines. The injectable, research-grade form has no human efficacy data and stays Unproven. It is not FDA-approved, and effects in humans beyond cosmetics are still being studied.
Jul 6, 2026 · MrPepTalks Editorial · 6 min read
SkincareUnprovenThe GLOW stack bundles GHK-Cu, BPC-157 and TB-500 for skin and recovery. Some of the parts have real research behind them — GHK-Cu as a topical especially — but the blend itself has never been studied as a blend, and it is not FDA-approved. Unproven is a verdict about the combination, not a dismissal of every ingredient.
Jul 6, 2026 · MrPepTalks Editorial · 8 min readUnproven in humans. IGF-1 LR3 is a genuinely useful laboratory research tool with real cell and animal data behind it, but there are no controlled human trials supporting the muscle and recovery uses people chase. It is banned in sport and not FDA-approved. Fascinating molecule, thin human evidence.
Jul 6, 2026 · MrPepTalks Editorial · 5 min read
PerformanceUnprovenIpamorelin has a real, well-characterized mechanism and an early-pharmacology signal on growth-hormone release, but the outcomes people actually want, meaning recovery, body composition, and healthy aging, are not established in completed human trials. It is not FDA-approved and is sold for laboratory research use only.
Jul 6, 2026 · MrPepTalks Editorial · 6 min read
SkincareUnprovenKLOW bundles four peptides with four separate research stories, but the stack itself has never been studied as a stack. The strongest evidence in the bundle (topical GHK-Cu) is real; the weakest is mostly preclinical; and the combination's own benefits and interactions are inferred, not measured. It is not FDA-approved.
Jul 6, 2026 · MrPepTalks Editorial · 6 min read
PerformanceUnprovenMK-677 reliably raises growth-hormone and IGF-1 markers in human studies, which is more than most research compounds can show. But the downstream results people actually want are not established, and real safety signals in older and frail populations keep this an open question rather than a green light.
Jul 6, 2026 · MrPepTalks Editorial · 6 min readMOTS-c has a genuinely interesting story in cell and animal research around metabolism and exercise biology. In people, though, controlled trials are essentially missing — so for now this is a promising lab story with an unproven human verdict, and it is not FDA-approved.
Jul 6, 2026 · MrPepTalks Editorial · 5 min read
LongevityUnprovenNAD+ is real, essential, and genuinely declines with age, and its precursors reliably raise NAD+ blood markers in human studies. But the longevity, energy, and metabolic outcomes people actually want are not established, and the popular IV drip route has almost no controlled human data behind it. Interesting biology, thin payoff evidence.
Jul 6, 2026 · MrPepTalks Editorial · 7 min readPT-141 is one of the rare research peptides with real human trial data behind it — that data supported the branded prescription drug Vyleesi for one narrow use. Research-grade PT-141 sold for lab use is a different, unapproved product, and its side-effect picture deserves an honest read.
Jul 6, 2026 · MrPepTalks Editorial · 5 min read
GLP-1PromisingRetatrutide is one of the rare research peptides with genuine early human trial data — it is commonly researched for weight and metabolic outcomes, and its triple-agonist design is the reason it stands out. It is still investigational and not FDA-approved, and the research-grade material sold for lab use is not the trial drug, so an honest read holds the strong early data and the real caveats together.
Jul 6, 2026 · MrPepTalks Editorial · 5 min read
GLP-1ProvenSemaglutide is one of the few peptides with genuinely deep human evidence behind it, and that evidence supported the branded prescription drugs Ozempic and Wegovy for their specific approved uses. Research-grade semaglutide sold for lab use is a different, unapproved product — so the strong data is real, but reading it as a green light for the research-grade vial is exactly the leap it does not support.
Jul 6, 2026 · MrPepTalks Editorial · 6 min readPromising but unproven. SS-31 (elamipretide) has real early-stage human trials behind it — more than most peptides in this space — but the results are mixed and it is not FDA-approved. Interesting to watch, not a settled answer.
Jul 6, 2026 · MrPepTalks Editorial · 5 min read
RecoveryRiskyTB-500 is commonly researched for tissue repair and recovery, and the underlying thymosin beta-4 biology is real and interesting. But the human efficacy evidence is thin, the compound is on the WADA prohibited list, and gray-market supply carries real contamination and mislabeling risk — which is why the honest label here is risky rather than merely unproven.
Jul 6, 2026 · MrPepTalks Editorial · 6 min readTesamorelin is one of the rare research peptides with real human trial data behind it — that data supported the branded prescription drug Egrifta for one narrow use. Research-grade tesamorelin sold for lab use is a different, unapproved product, and its side-effect picture deserves an honest read.
Jul 6, 2026 · MrPepTalks Editorial · 5 min readThymosin Alpha-1 is one of the more genuinely interesting immune peptides — it has real human research behind it in some countries, which is more than most peptides in this space can say. But that research clusters around specific medical contexts, not the general wellness use people ask about, and in the US it is sold as an unapproved research chemical. Promising, honestly framed, not a sure thing.
Jul 6, 2026 · MrPepTalks Editorial · 5 min read
GLP-1PromisingTirzepatide is one of the few research peptides with a genuine human trial program behind it — that data supported the branded prescription drugs Mounjaro and Zepbound, which reached the market for narrow indications. Research-grade tirzepatide sold for lab use is a different, unapproved product, and its side-effect and sourcing picture deserves an honest read.
Jul 6, 2026 · MrPepTalks Editorial · 5 min readGet each new breakdown the week it drops — plus the printable cheat sheet. Free, no hype.
No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.